For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| VARIVAX | Attenuated live varicella vaccine was administered in usual practice. Recommended dosing is a single 0.5 mL subcutaneous injection in children 12 months to 12 years of age. | None | None | 4 | 727 | 105 | 727 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| Pyrexia | None | General disorders | MedDRA (15.0) | View |
| Bronchitis | None | Infections and infestations | MedDRA (15.0) | View |
| Pneumonia | None | Infections and infestations | MedDRA (15.0) | View |
| Decreased appetite | None | Metabolism and nutrition disorders | MedDRA (15.0) | View |
| Oliguria | None | Renal and urinary disorders | MedDRA (15.0) | View |